Option Care Health’s (OPCH) Market Outperform Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a research note published on Wednesday,Benzinga reports. JMP Securities currently has a $36.00 price objective on the stock.

Several other equities research analysts have also recently commented on OPCH. JPMorgan Chase & Co. increased their price objective on Option Care Health from $40.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, March 6th. Barrington Research restated an “outperform” rating and set a $38.00 target price on shares of Option Care Health in a research note on Wednesday, April 30th. Finally, UBS Group raised shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $38.00 to $40.00 in a report on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Option Care Health Trading Down 0.1%

OPCH opened at $31.53 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.54 and a debt-to-equity ratio of 0.82. Option Care Health has a 52 week low of $21.39 and a 52 week high of $35.53. The stock has a market cap of $5.16 billion, a PE ratio of 25.43, a PEG ratio of 1.91 and a beta of 0.74. The business has a 50 day moving average of $32.08 and a 200-day moving average of $30.53.

Option Care Health (NASDAQ:OPCH) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.26 billion. Option Care Health had a return on equity of 16.90% and a net margin of 4.12%. The company’s revenue was up 16.3% on a year-over-year basis. During the same period last year, the company earned $0.26 earnings per share. Equities research analysts predict that Option Care Health will post 1.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Option Care Health

Several institutional investors and hedge funds have recently bought and sold shares of OPCH. JPMorgan Chase & Co. raised its position in shares of Option Care Health by 29.6% during the 4th quarter. JPMorgan Chase & Co. now owns 1,511,403 shares of the company’s stock valued at $35,065,000 after purchasing an additional 344,875 shares during the period. MetLife Investment Management LLC increased its stake in Option Care Health by 7.8% in the 4th quarter. MetLife Investment Management LLC now owns 197,219 shares of the company’s stock worth $4,575,000 after buying an additional 14,311 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Option Care Health by 6.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company’s stock valued at $58,235,000 after acquiring an additional 147,054 shares during the period. Global Alpha Capital Management Ltd. raised its holdings in Option Care Health by 38.1% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company’s stock valued at $1,596,000 after acquiring an additional 18,992 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Option Care Health in the fourth quarter valued at about $327,000. 98.05% of the stock is currently owned by hedge funds and other institutional investors.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.